Details for Patent: 7,598,257
✉ Email this page to a colleague
Which drugs does patent 7,598,257 protect, and when does it expire?
Patent 7,598,257 protects OPZELURA and JAKAFI and is included in two NDAs.
Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and fifty-three patent family members in thirty-five countries.
Summary for Patent: 7,598,257
| Title: | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| Abstract: | The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. |
| Inventor(s): | Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Voorhees, NJ) |
| Assignee: | Incyte Corporation (Wilmington, DE) |
| Application Number: | 11/637,545 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,598,257 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; Use; |
Drugs Protected by US Patent 7,598,257
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-001 | Nov 16, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-003 | Nov 16, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-004 | Nov 16, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,598,257
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1966202 | ⤷ Sign Up | C300574 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1966202 | ⤷ Sign Up | PA2013002 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1966202 | ⤷ Sign Up | CA 2013 00005 | Denmark | ⤷ Sign Up |
| European Patent Office | 1966202 | ⤷ Sign Up | C20130003 00072 | Estonia | ⤷ Sign Up |
| European Patent Office | 1966202 | ⤷ Sign Up | 1390005-5 | Sweden | ⤷ Sign Up |
| European Patent Office | 1966202 | ⤷ Sign Up | 92137 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
